Less Established companies with few products or limited experience supplying APIs to regulated markets

Established companies with a long track record of supplying APIs to regulated markets

Opportunities for growth and expansion

3,200+ companies involved in API production

The generics industry is poised for some major shifts over the next few years thanks to more products, new markets and higher-margin activities. Let’s look at learnings from the current landscape to understand where the industry is headed.

Potential Future companies have interest in supplying regulated markets, but with limited or no known performance

Emerging leaders in generics manufacturing

Regional strategies

Average number of APIs in a manufacturer’s portfolio

Companies are diversifying their capabilities

Firms’ strategies include affiliating themselves with finished-dose or U.S. generics activity.

Maintaining quality standards is more critical than ever

Proportion of companies receiving FDA inspections 2016-present

Potential Future suppliers have been inspected since 2016 but do not hold active DMFs yet.

Investment opportunities in specialty products

2018 U.S. FDA novel drug approvals serve as an indicator for where the market is going and which manufacturing technologies API suppliers will need to invest in.

Characteristics of an emerging leader

Regardless of a manufacturer’s current capabilities, firms can take advantage of the many opportunities in the generics space.

Grow your generics or API business

Strategically develop your portfolio, gain insight on when drugs go off patent, and penetrate new markets. Visit our website to learn more: clarivate.com/genericsintelligence

© 2019 Clarivate Analytics its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.